Nevirapine Medical Valley (Nevirapine)

Nevirapine is an antiretroviral drug that targets HIV‑1 replication. It is used in the following clinical situations:

• HIV‑1 infection in adults: reduces plasma viral load when combined with other antiretrovirals.
• HIV‑1 infection in children: provides pediatric dosing options as part of combination therapy.
• HIV‑1 infection in treatment‑naïve patients: forms part of first‑line regimens to achieve sustained viral suppression.

• Nevirapine binds to a specific allosteric site on the HIV reverse transcriptase enzyme, inducing a conformational change that impairs both RNA‑dependent and DNA‑dependent DNA polymerase activities. This inhibition prevents the synthesis of viral DNA from the RNA template, thereby blocking HIV replication and reducing viral load in infected individuals.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Rash: mild to moderate skin eruptions.
• Gastrointestinal upset: nausea, vomiting, or abdominal discomfort.
• Headache: transient mild headache.
• Fatigue: general tiredness or weakness.
• Elevated liver enzymes: mild, transient increases in hepatic transaminases.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
• Toxic epidermal necrolysis: life‑threatening skin detachment.
• Hepatotoxicity: significant liver injury, jaundice, or hepatitis.
• Severe hypersensitivity reactions: including fever, eosinophilia, and organ involvement.
• Hematologic abnormalities: neutropenia or anemia.

Before initiating therapy, clinicians should consider the following precautions:

• Hepatic function: assess baseline liver enzymes and monitor regularly during treatment.
• Skin reactions: educate patients to report any rash promptly, especially within the first 8 weeks.
• Pregnancy: avoid use unless the benefits outweigh potential risks, as safety data are limited.
• Drug resistance: avoid monotherapy; use in combination with other antiretrovirals to prevent resistance development.
• Drug interactions: review concomitant medications for potential CYP450 interactions.
• Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Nevirapine can affect the metabolism of several co‑administered drugs.

Major Interactions (Avoid)

• Rifampicin: markedly reduces nevirapine plasma levels, compromising efficacy.
• Certain protease inhibitors (e.g., ritonavir): may increase nevirapine concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Warfarin: nevirapine may alter anticoagulant effect; monitor INR.
• Oral contraceptives: reduced hormonal efficacy; consider alternative contraception.
• Efavirenz: combined use may increase hepatotoxicity; monitor liver function.